Published in Cancer on May 15, 2004
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatr Blood Cancer (2015) 2.88
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol (2006) 1.20
Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak (2008) 1.15
Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma (2011) 1.07
Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 1.06
Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care (2006) 1.06
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer (2012) 0.99
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol (2006) 0.96
Chemotherapy-associated renal dysfunction. Nat Rev Nephrol (2009) 0.95
Beneficial effects of montelukast against methotrexate-induced liver toxicity: a biochemical and histological study. ScientificWorldJournal (2012) 0.90
Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit (2011) 0.88
Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer Res Treat (2005) 0.87
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy (2013) 0.86
Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity. J Med Toxicol (2008) 0.83
Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol (2013) 0.83
Cause and outcome of cerebellar mutism: evidence from a systematic review. Childs Nerv Syst (2014) 0.82
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget (2016) 0.82
High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. Am J Blood Res (2012) 0.79
Protective effects of carvacrol against methotrexate-induced testicular toxicity in rats. Int J Clin Exp Med (2014) 0.78
Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study. Pediatr Nephrol (2015) 0.75
Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic Acid and high flux dialysis. Indian J Hematol Blood Transfus (2012) 0.75
The utility of online haemodiafiltration in methotrexate poisoning. BMJ Case Rep (2014) 0.75
Recent new drug approvals. Part 1: drugs with pediatric indications. J Pediatr Pharmacol Ther (2012) 0.75
High-flux hemodialysis after administering high-dose methotrexate in a patient with posttransplant lymphoproliferative disease and impaired renal function. Clin Case Rep (2015) 0.75
High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma (2013) 0.75
Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients. Chin Med J (Engl) (2016) 0.75
Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase. Clin Kidney J (2014) 0.75
Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effects. BMC Complement Altern Med (2016) 0.75
The protective effect of intraperitoneal medical ozone preconditioning and treatment on hepatotoxicity induced by methotrexate. Int J Clin Exp Med (2015) 0.75
Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. P T (2013) 0.75
Does intraperitoneal medical ozone preconditioning and treatment ameliorate the methotrexate induced nephrotoxicity in rats? Int J Clin Exp Med (2015) 0.75
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell (2007) 10.13
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol (2002) 10.03
Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol (2007) 5.50
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol (2003) 3.93
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med (2010) 3.86
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med (2006) 3.11
Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev (2006) 2.85
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol (2012) 2.67
Understanding and managing methotrexate nephrotoxicity. Oncologist (2006) 2.52
Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer (2011) 2.49
Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol (2008) 2.46
Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev (2004) 2.20
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol (2010) 2.05
Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med (2004) 2.05
Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol (2003) 1.99
Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol (2008) 1.95
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol (2003) 1.79
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol (2010) 1.65
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics (2005) 1.62
Declining childhood and adolescent cancer mortality. Cancer (2014) 1.62
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst (2004) 1.62
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res (2007) 1.61
Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer (2002) 1.60
Evaluation of ocular surface disorders: a new diagnostic tool based on impression cytology and confocal laser scanning microscopy. Br J Ophthalmol (2009) 1.59
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005) 1.57
Long-term effectiveness of autologous cultured limbal stem cell grafts in patients with limbal stem cell deficiency due to chemical burns. Clin Experiment Ophthalmol (2011) 1.56
Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med (2002) 1.53
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia (2012) 1.49
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol (2005) 1.48
Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol (2007) 1.46
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem (2005) 1.44
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol (2005) 1.40
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol (2006) 1.40
CT scans in young people in Northern England: trends and patterns 1993-2002. Pediatr Radiol (2011) 1.37
Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol (2007) 1.36
Clinical trial design for target-based therapy. Oncologist (2002) 1.36
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer (2008) 1.35
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34
Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol (2009) 1.33
DNA end resection by CtIP and exonuclease 1 prevents genomic instability. EMBO Rep (2010) 1.33
Msx2 and necdin combined activities are required for smooth muscle differentiation in mesoangioblast stem cells. Circ Res (2004) 1.33
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res (2012) 1.33
A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J (2003) 1.32
Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol (2003) 1.32
Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori (2007) 1.31
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2007) 1.31
A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res (2007) 1.29
Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol (2004) 1.29
High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol (2008) 1.27
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol (2003) 1.27
Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer (2009) 1.26
Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst (2002) 1.26
The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med (2004) 1.26
Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res (2010) 1.25
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol (2008) 1.24
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol (2010) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Degradation of human exonuclease 1b upon DNA synthesis inhibition. Cancer Res (2005) 1.21
Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs (2010) 1.21
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol (2009) 1.20
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial. J Thorac Cardiovasc Surg (2008) 1.18
Stature of young people with malignant bone tumors. Pediatr Blood Cancer (2004) 1.17
Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol (2006) 1.17
Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives. J Clin Oncol (2004) 1.17
Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer (2005) 1.16
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (2004) 1.16
Treatment of metastatic retinoblastoma. Ophthalmology (2003) 1.15
Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome. Neurology (2013) 1.15
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol (2015) 1.14
The role of radiotherapy in oseosarcoma. Cancer Treat Res (2009) 1.14
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol (2008) 1.13
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res (2012) 1.13
ATR-dependent pathways control hEXO1 stability in response to stalled forks. Nucleic Acids Res (2007) 1.13
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res (2004) 1.13
Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand (2003) 1.12